Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Genitourinary Cancer

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial

JAMA Oncol

Sushentsev N, Warren AY, Colling R, Verrill C, Pazukhina E, Blyuss O, Seibert TM, Barrett T, Mills IG, Bryant RJ, Donovan JL, Neal DE, Hamdy FC

doi: 10.1001/jamaoncol.2025.4125

Genitourinary Cancer

Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Prostate

Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC

doi: 10.1002/pros.70167

Genitourinary Cancer

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

Eur Urol

Ghadjar P, Hayoz S, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Hoffmann E, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Riesterer O, Beck M, Thalmann GN, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.eururo.2025.12.020

SABCS 2025

Breast Cancer

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

Genitourinary Cancer

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Eur Urol

Vigneswaran HT, Palsdottir T, Micoli C, Tilki D, Lin D, Cooperberg M, Eggener S, Falagario UG, Möller A, Aly M, Akre O, Wiklund P, Egevad L, Grönberg H, Nordström T, Eklund M

doi: 10.1016/j.eururo.2025.10.001

Genitourinary Cancer

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy

Prostate

Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, Bahary JP, Pisansky TM, Zeitzer KL, Gore E, Efstathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong A, Dess RT, McGinnis LS, Kuettel M, DeMora L, Sandler HM

doi: 10.1002/pros.70018

Breast Cancer

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Int J Cancer

Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA

doi: 10.1002/ijc.70037

Genitourinary Cancer

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy

Eur Urol

Heck MM, Lehmann J, Amiel T, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Rexer H, Retz M, Gschwend JE

doi: 10.1016/j.eururo.2025.09.001

Genitourinary Cancer

Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial

Eur Urol

Graefen M, Falkenbach F, Maurer T, Budäus L, Tilki D, Karakiewicz PI, Aly M, Wiklund P, Brasso K, Røder A, Poulsen MH, Schostak M, Görtzen C, Renter A, von Amsberg G, Haese A, Heinzer H, Salomon G, Steuber T, Beyer B

doi: 10.1016/j.eururo.2025.09.4144

Related content

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial

Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy

Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial